Theophylline Level
No Results
No Results
processing….
Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke. [6] In the blood, 40%-50% of theophylline is bound to proteins.
The reference therapeutic ranges of theophylline are listed below.
Reference ranges of theophylline in the treatment asthma vary by age, as follows:
Adults: 5-15 µg/mL
Children: 5-10 µg/mL
The reference range of theophylline in the treatment of acute bronchospasm in adults is 10-15 µg/mL.
The reference range of theophylline in the treatment of neonatal apnea is 6-11 µg/mL.
Serum values of theophylline that fall within the established reference ranges allow for the desired therapeutic effect while minimizing the drug’s side effects. [1] It also lets the clinician know when the dose of theophylline can be adjusted within this range to achieve a therapeutic effect if the patient is still experiencing symptoms.
A low level of theophylline may not produce the desired outcome. Values below 10 µg/mL have small effects on bronchospasm, and those below 5 µg/mL may not offer benefit in the treatment of asthma. [1]
Increased clearance of theophylline and the low levels that result are caused by the consumption of barbecued meats; youth (age 1-16 years); low-carbohydrate, high-protein diets; acidosis; and smoking cigarettes and marijuana. [1, 2, 3] Concomitant administration of phenytoin, phenobarbital, and rifampin can lead to increased clearance of and therefore low levels of theophylline. [1, 2]
High serum theophylline levels increase the risk of toxicity. Toxic effects include nausea and vomiting, headaches, gastric discomfort, diuresis, insomnia, cardiac arrhythmias, behavioral disturbances, and epileptic seizures. [1, 2]
Decreased theophylline clearance and the resulting higher-than-predicted serum levels of the drug are caused by pneumonia; heart failure; infections; influenza vaccination; liver disease; chronic obstructive pulmonary disease (COPD); obesity; a high-carbohydrate, low-protein diet; high levels of dietary methylxanthines (eg, caffeine); and the extremes of age (ie, age 0-1 years and elderly). [1, 2, 3] Administration of allopurinol, oral contraceptives, cimetidine, erythromycin, quinolone antibiotics, fluvoxamine, zileuton, and zafirlukast has been shown to increase theophylline levels. [1, 2, 3]
Specimen: Blood
Container: Red-top tube, light-green–top tube
Method: Routine venipuncture
In order to accurately measure serum theophylline levels after oral administration, blood should be drawn 3 days after the initiation of therapy or dose change, when the steady-state peak blood concentration has been reached. This assumes that no doses have been missed or added and that none have been taken at unequal intervals. [4] Once this steady state has been achieved, theophylline levels should be measured 1-2 hours after administration of an oral solution or immediate-release tablet or 4-12 hours after administration of an extended-release tablet. [4]
If the drug is given intravenously, a sample should be drawn 30 minutes after completion of a loading dose to determine if concentrations are less than 10 µg/mL, indicating the need for another loading dose, or greater than 20 µg/mL, indicating the need for delay in initiating maintenance intravenous therapy. [5]
Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke. [6] In the blood, 40%-50% of theophylline is bound to proteins.
Theophylline is metabolized in the liver by the hepatic P450 system enzymes CYP1A2 and CYP3A4 into its metabolites 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine before being excreted in the urine. [6]
Mechanisms of action
There is no single accepted mechanism of action for theophylline, although many have been proposed.
First and foremost, theophylline is a bronchodilator but also has many molecular-level actions that still may be useful in the treatment of airway disease.
Theophylline nonselectively inhibits phosphodiesterases, which elevates cellular levels of cAMP and cGMP, accounting for the bronchodilator effect seen in the treatment of asthma and COPD. Therapeutic levels of theophylline also antagonize adenosine receptors, also contributing to bronchodilation, since adenosine causes bronchoconstriction in persons with asthma via the release of histamine and leukotrienes.
Theophylline has also been shown to increase the release of interleukin-10, which has many anti-inflammatory effects. Higher theophylline concentrations and inhibition of phosphodiesterase affect gene transcription by preventing translocation of the pro-inflammatory transcription factor NF-kB to the nucleus via a protective effect on the degradation of the inhibitory protein I-kba.
Theophylline has also been shown, in vitro, to promote apoptosis in eosinophils and neutrophils, the cells that perpetuate chronic inflammation in asthma and COPD.
Theophylline also activates histone deacetylase, which enhances the anti-inflammatory effects of corticosteroids, which are often used simultaneously in the treatment of asthma and COPD.
Finally, theophylline has some less-understood and less-studied effects at higher-than-therapeutic concentrations, such as increasing circulating catecholamines, inhibiting calcium influx into inflammatory cells, inhibiting prostaglandin effects, and antagonizing tumor necrosis factor-alpha. [1]
Measuring serum theophylline levels is indicated when initiating therapy to guide final dosage adjustments after titration, before increasing the dosage in patients with persistent symptoms, if manifestations of toxicity are present, upon new or worsening illness, or when a change in treatment regimen alters theophylline clearance. [4, 5]
Goodman, Louis S, Laurence L. Brunton, Bruce Chabner, and Bjorn C. Knollmann. Pulmonary Pharmacology.” Goodman & Gilman’s Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2011. Chapter 36.
Aronson, J K M Hardman, DJ Reynolds. “ABC of Monitoring Drug Therapy: Theophylline.” BMJ. 1992. 305- 6865: 1355-358.
Bukowskyj M, Nakatsu K, Munt PW. Theophylline reassessed. Ann Intern Med. 1984 Jul. 101(1):63-73. [Medline].
Inwood Laboratories. Theophylline extended-release capsules prescribing information. Inwood. NY: 2005 Mar.
American Regent Laboratories, Inc. Aminophylline injection, USP prescribing information. Shirley. NY: 1999 June.
Available at http://reference.medscape.com/drug/theo-dur-quibron-t-sr-theophylline-343447#0. Medscape: Theophylline.
Scott Blumhof, DO Resident Physician, Department of Internal Medicine, Albert Einstein Medical Center
Scott Blumhof, DO is a member of the following medical societies: American College of Physicians, American Osteopathic Association
Disclosure: Nothing to disclose.
Glenn Eiger, MD Director of Internal Medicine Residency Program, Associate Chairman, Department of Medicine, Albert Einstein Medical Center
Glenn Eiger, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Phi Beta Kappa, Association of Program Directors in Internal Medicine
Disclosure: Nothing to disclose.
Eric B Staros, MD Associate Professor of Pathology, St Louis University School of Medicine; Director of Clinical Laboratories, Director of Cytopathology, Department of Pathology, St Louis University Hospital
Eric B Staros, MD is a member of the following medical societies: American Medical Association, American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology
Disclosure: Nothing to disclose.
Theophylline Level
Research & References of Theophylline Level |A&C Accounting And Tax Services
Source